506-82-1Relevant articles and documents
McCoy,Allred
, p. 912 (1962)
Mixed alkyl dialkylthiocarbamates of zinc and cadmium: Potential precursors for II/VI materials. X-ray crystal structure of [MeZnS2CNEt2]2
Hursthouse, Michael B.,Malik, M. Azad,Motevalli, Majid,O'Brien, Paul
, p. 730 - 732 (1991)
Compounds with the formula RMS2CNR′2 (R or R′ = Me or Et, M = Zn; R = Me, R′ = Et, M = Cd) have been synthesized and characterized. An X-ray crystal structure for MeZnS2CNEt2 has been determined and shows the complex to be dimeric. The compound crystallizes in space group P21/c, a = 6.776 (1) ?, b = 10.341 (4) ?, and c = 10.341 (4) ?, α = 90°, β = 97.3 (3)°, and γ = 90°. The zinc complexes may be useful precursors for the deposition of ZnS.
Exchange of alkyl and tris(2-mercapto-1-t-butylimidazolyl)hydroborato ligands between zinc, cadmium and mercury
Kreider-Mueller, Ava,Quinlivan, Patrick J.,Rong, Yi,Owen, Jonathan S.,Parkin, Gerard
, p. 177 - 183 (2015)
Abstract The tris(2-mercaptoimidazolyl)hydroborato ligand, [TmBut], has been used to investigate the exchange of alkyl and sulfur donor ligands between the Group 12 metals, Zn, Cd and Hg. For example, [TmBut]2Zn reacts with Me2Zn to yield [TmBut]ZnMe, while [TmBut]CdMe is obtained readily upon reaction of [TmBut]2Cd with Me2Cd. Ligand exchange is also observed between different metal centers. For example, [TmBut]CdMe reacts with Me2Zn to afford [TmBut]ZnMe and Me2Cd. Likewise, [TmBut]HgMe reacts with Me2Zn to afford [TmBut]ZnMe and Me2Hg. However, whereas the [TmBut] ligand transfers from mercury to zinc in the methyl system, [TmBut]HgMe/Me2Zn, transfer of the [TmBut] ligand from zinc to mercury is observed upon treatment of [TmBut]2Zn with HgI2 to afford [TmBut]HgI and [TmBut]ZnI. These observations demonstrate that the phenomenological preference for the [TmBut] ligand to bind one metal rather than another is strongly influenced by the nature of the co-ligands.
Liu,Asprey
, p. 249,250,251,252,253 (1979)
Method for treating cancers using a diiodo thyronine analogue having no significant hormonal activity and a vinca alkaloid and compositions comprising the same
-
, (2008/06/13)
The present invention is directed to a method for treating cancers by administering a pharmaceutically effective amount of a diiodo thyronine analogue having no significant hormonal activity and a vinca alkaloid or biologically active analog thereof. The present invention also features novel pharmaceutical compositions comprising the same.